{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:57:53Z","timestamp":1792645073490,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA227656"],"award-info":[{"award-number":["R37CA227656"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015087","name":"Markey Cancer Center, University of Kentucky","doi-asserted-by":"publisher","award":["P30CA177558"],"award-info":[{"award-number":["P30CA177558"]}],"id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.biopha.2023.116013","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T04:30:02Z","timestamp":1702701002000},"page":"116013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt\/\u03b2-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"170","author":[{"given":"Majd A.","family":"Al-Hamaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna H.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan G.","family":"Haney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6811-0568","authenticated-orcid":false,"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Arvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Sampathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4334-2495","authenticated-orcid":false,"given":"Mary","family":"Wimsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-4474","authenticated-orcid":false,"given":"Chunming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.116013_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.pmbts.2017.11.002","article-title":"Wnt signaling in hematological malignancies","volume":"153","author":"Grainger","year":"2018","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.biopha.2023.116013_bib2","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3389\/fimmu.2019.02854","article-title":"WNT signaling in tumors: the way to evade drugs and immunity","volume":"10","author":"Martin-Orozco","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2023.116013_bib3","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biopha.2023.116013_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell stem Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.biopha.2023.116013_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","article-title":"The Wnt signaling pathway in development and disease","volume":"20","author":"Logan","year":"2004","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2023.116013_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.biopha.2018.11.082","article-title":"Therapeutic potential of targeting the Wnt\/\u03b2-catenin signaling pathway in colorectal cancer","volume":"110","author":"Cheng","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.116013_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110851","article-title":"WNT\/\u03b2-catenin signaling in the development of liver cancers","volume":"132","author":"He","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.biopha.2023.116013_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2174\/138945010792006780","article-title":"A Wnt-ow of opportunity: targeting the Wnt\/\u03b2-catenin pathway in breast cancer","volume":"11","author":"R Prosperi","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.biopha.2023.116013_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2023.116013_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","article-title":"Wnt\/\u03b2-catenin signaling in cancer stemness and malignant behavior","volume":"19","author":"Fodde","year":"2007","journal-title":"Curr. Opin. Cell Biol."},{"issue":"7","key":"10.1016\/j.biopha.2023.116013_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/cancers8070060","article-title":"Wnt signaling in cancer stem cell biology","volume":"8","author":"De Sousa e Melo","year":"2016","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2023.116013_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ceb.2013.01.004","article-title":"Wnt signaling in stem and cancer stem cells","volume":"25","author":"Holland","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"issue":"2","key":"10.1016\/j.biopha.2023.116013_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mc.23277","article-title":"Breast cancer stem cells: a review of their characteristics and the agents that affect them","volume":"60","author":"Shan","year":"2021","journal-title":"Mol. Carcinog."},{"issue":"6","key":"10.1016\/j.biopha.2023.116013_bib15","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2353\/ajpath.2010.091125","article-title":"Wnt\/\u03b2-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome","volume":"176","author":"Khramtsov","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2023.116013_bib16","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/0008-5472.CAN-21-0184","article-title":"EPHB2 activates \u03b2-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma","volume":"81","author":"Leung","year":"2021","journal-title":"Cancer Res."},{"issue":"532","key":"10.1016\/j.biopha.2023.116013_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay7522","article-title":"Wnt-mediated endothelial transformation into mesenchymal stem cell\u2013like cells induces chemoresistance in glioblastoma","volume":"12","author":"Huang","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.116013_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.12","article-title":"Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia","volume":"4","author":"Ng","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2023.116013_bib19","unstructured":"Panelli, P., et al., Non-canonical \u03b2-Catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia. Blood, 2022."},{"issue":"25","key":"10.1016\/j.biopha.2023.116013_bib20","first-page":"3917","article-title":"Leukemia stem cells in T-ALL require active Hif1\u03b1 and Wnt signaling","volume":"125","author":"Giambra","year":"2015","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2023.116013_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","article-title":"Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond \u03b2-catenin and the destruction complex","volume":"52","author":"Jung","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2023.116013_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrm3470","article-title":"The complex world of WNT receptor signalling","volume":"13","author":"Niehrs","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.biopha.2023.116013_bib23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cells12081110","article-title":"A New Wave of Targeting \u2018Undruggable\u2019Wnt Signaling for Cancer Therapy: Challenges and Opportunities","volume":"12","author":"Park","year":"2023","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.biopha.2023.116013_bib24","doi-asserted-by":"crossref","first-page":"20395","DOI":"10.18632\/oncotarget.7954","article-title":"CWP232228 targets liver cancer stem cells through Wnt\/\u03b2-catenin signaling: a novel therapeutic approach for liver cancer treatment","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biopha.2023.116013_bib25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s11626-015-9931-x","article-title":"PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt\/\u03b2-catenin signaling pathway","volume":"51","author":"Shi","year":"2015","journal-title":"Vitr. Cell. Dev. Biol. -Anim."},{"issue":"10","key":"10.1016\/j.biopha.2023.116013_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd4627","article-title":"Zebrafish as tools for drug discovery","volume":"14","author":"MacRae","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2023.116013_bib27","article-title":"Zebrafish as a powerful alternative model organism for preclinical investigation of nanomedicines","author":"Sharma","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-91612-6","article-title":"Spatiotemporal imaging and pharmacokinetics of fluorescent compounds in zebrafish eleuthero-embryos after different routes of administration","volume":"11","author":"Guarin","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2023.116013_bib29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/neuonc\/noab264","article-title":"Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts","volume":"24","author":"Almstedt","year":"2022","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.biopha.2023.116013_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymeth.2015.11.021","article-title":"Tools for automating the imaging of zebrafish larvae","volume":"96","author":"Pulak","year":"2016","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib31","article-title":"Quantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"issue":"158","key":"10.1016\/j.biopha.2023.116013_bib32","article-title":"Drug screening of primary patient derived tumor xenografts in zebrafish","author":"Haney","year":"2020","journal-title":"JoVE (J. Vis. Exp. )"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib33","first-page":"1","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ydbio.2012.07.016","article-title":"Visualization and exploration of Tcf\/Lef function using a highly responsive Wnt\/\u03b2-catenin signaling-reporter transgenic zebrafish","volume":"370","author":"Shimizu","year":"2012","journal-title":"Dev. Biol."},{"issue":"16","key":"10.1016\/j.biopha.2023.116013_bib35","first-page":"3296","article-title":"High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia","volume":"115","author":"Smith","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"19","key":"10.1016\/j.biopha.2023.116013_bib36","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1128\/MCB.00373-15","article-title":"Deubiquitinase USP47\/UBP64E Regulates beta-Catenin Ubiquitination and Degradation and Plays a Positive Role in Wnt Signaling","volume":"35","author":"Shi","year":"2015","journal-title":"Mol. Cell Biol."},{"issue":"24","key":"10.1016\/j.biopha.2023.116013_bib37","doi-asserted-by":"crossref","first-page":"11348","DOI":"10.1021\/acs.jmedchem.9b01685","article-title":"An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med Chem."},{"issue":"12","key":"10.1016\/j.biopha.2023.116013_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101795","article-title":"Epigenetic regulation of Wnt signaling by carboxamide-substituted benzhydryl amines that function as histone demethylase inhibitors","volume":"23","author":"Zhang","year":"2020","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.biopha.2023.116013_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100433","article-title":"Protocol for rapid assessment of the efficacy of novel Wnt inhibitors using zebrafish models","volume":"2","author":"Haney","year":"2021","journal-title":"STAR Protoc."},{"issue":"12","key":"10.1016\/j.biopha.2023.116013_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101795","article-title":"Epigenetic regulation of Wnt signaling by carboxamide-substituted benzhydryl amines that function as histone demethylase inhibitors","volume":"23","author":"Zhang","year":"2020","journal-title":"Iscience"},{"issue":"3","key":"10.1016\/j.biopha.2023.116013_bib41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ccr.2014.01.032","article-title":"Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt\/mTORC1 pathway activation","volume":"25","author":"Blackburn","year":"2014","journal-title":"Cancer Cell"},{"issue":"53","key":"10.1016\/j.biopha.2023.116013_bib42","article-title":"Quantifying the frequency of tumor-propagating cells using limiting dilution cell transplantation in syngeneic zebrafish","author":"Blackburn","year":"2011","journal-title":"JoVE (J. Vis. Exp. )"},{"issue":"1-2","key":"10.1016\/j.biopha.2023.116013_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J. Immunol. Methods"},{"issue":"7264","key":"10.1016\/j.biopha.2023.116013_bib44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nature08356","article-title":"Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling","volume":"461","author":"Huang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.116013_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-7-273","article-title":"Cytotoxicity and activation of the Wnt\/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors","volume":"7","author":"Naujok","year":"2014","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.biopha.2023.116013_bib46","doi-asserted-by":"crossref","unstructured":"Stoick-Cooper, C.L., et al., Distinct Wnt signaling pathways have opposing roles in appendage regeneration. 2007.","DOI":"10.1242\/dev.001123"},{"issue":"4","key":"10.1016\/j.biopha.2023.116013_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1527-3466.2004.tb00146.x","article-title":"Candesartan","volume":"22","author":"Gleiter","year":"2004","journal-title":"Cardiovasc Drug Rev."},{"key":"10.1016\/j.biopha.2023.116013_bib48","first-page":"863","article-title":"Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer","volume":"20","author":"Tabatabai","year":"2021","journal-title":"Excli J."},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89668-5","article-title":"A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)","volume":"11","author":"Rivas","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2023.116013_bib50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.5114\/aoms.2012.30955","article-title":"Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells","volume":"9","author":"Piastowska-Ciesielska","year":"2013","journal-title":"Arch. Med Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.116013_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.canlet.2012.10.006","article-title":"Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer","volume":"328","author":"Chen","year":"2013","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.biopha.2023.116013_bib52","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/01.CIR.102.21.2665","article-title":"Cardiovascular drugs. Dofetilide","volume":"102","author":"Mounsey","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.116013_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.podrm.2019.10.004","article-title":"Erlotinib","volume":"45","author":"Abdelgalil","year":"2020","journal-title":"Profiles Drug Subst. Excip. Relat. Method."},{"issue":"6","key":"10.1016\/j.biopha.2023.116013_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/ERC-22-0022","article-title":"Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma","volume":"29","author":"Choi","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2023.116013_bib55","unstructured":"Correa, R., Q. Rodriguez, and T.M. Nappe, Glipizide. 2017."},{"key":"10.1016\/j.biopha.2023.116013_bib56","doi-asserted-by":"crossref","first-page":"27819","DOI":"10.1038\/srep27819","article-title":"Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis","volume":"6","author":"Qi","year":"2016","journal-title":"Sci. Rep."},{"issue":"59","key":"10.1016\/j.biopha.2023.116013_bib57","doi-asserted-by":"crossref","first-page":"100021","DOI":"10.18632\/oncotarget.21754","article-title":"Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via Akt\/mTOR\/autophagy pathways","volume":"8","author":"Nazim","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3747\/co.v18i1.708","article-title":"Oxaliplatin: a review in the era of molecularly targeted therapy","volume":"18","author":"Alcindor","year":"2011","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2023.116013_bib59","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/sj.bjc.6602215","article-title":"Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells","volume":"91","author":"Arango","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.116013_bib60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol. (Dordr. )"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12967-016-0875-z","article-title":"Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin","volume":"14","author":"Hall","year":"2016","journal-title":"J. Transl. Med"},{"issue":"9","key":"10.1016\/j.biopha.2023.116013_bib62","first-page":"1090","article-title":"Ticlopidine and antiplatelet therapy","volume":"27","author":"Flores-Runk","year":"1993","journal-title":"Ann. Pharm."},{"issue":"48","key":"10.1016\/j.biopha.2023.116013_bib63","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1073\/pnas.0505259102","article-title":"Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice","volume":"102","author":"Cl\u00e9ment-Lacroix","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2023.116013_bib64","first-page":"863","article-title":"Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer","volume":"20","author":"Tabatabai","year":"2021","journal-title":"Excli J."},{"issue":"10","key":"10.1016\/j.biopha.2023.116013_bib65","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrd2137","article-title":"Tumour-initiating cells: challenges and opportunities for anticancer drug discovery","volume":"8","author":"Zhou","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"13","key":"10.1016\/j.biopha.2023.116013_bib66","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-05-0626","article-title":"Isolation and in vitro propagation of tumorigenic breast cancer cells with stem\/progenitor cell properties","volume":"65","author":"Ponti","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.116013_bib67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fonc.2018.00347","article-title":"Sphere-formation assay: three-dimensional in vitro culturing of prostate cancer stem\/progenitor sphere-forming cells","volume":"8","author":"Bahmad","year":"2018","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.116013_bib68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/adt.2014.573","article-title":"Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors","volume":"12","author":"Edmondson","year":"2014","journal-title":"Assay. Drug Dev. Technol."},{"issue":"4","key":"10.1016\/j.biopha.2023.116013_bib69","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1254\/jphs.13025FP","article-title":"Multi-drug\u2013resistant cells enriched from chronic myeloid leukemia cells by doxorubicin possess tumor-initiating\u2013cell properties","volume":"122","author":"Xin","year":"2013","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3747\/co.23.2806","article-title":"Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia?","volume":"23","author":"Belmonte","year":"2016","journal-title":"Curr. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2023.116013_bib71","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.3390\/ijms24087147","article-title":"ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives","volume":"24","author":"Damiani","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.116013_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-016-0080-5","article-title":"CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia","volume":"4","author":"Jiang","year":"2016","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.116013_bib73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell stem Cell"},{"key":"10.1016\/j.biopha.2023.116013_bib74","first-page":"1207","article-title":"Targeting cancer stem cells: emerging role of Nanog transcription factor","author":"Wang","year":"2013","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.biopha.2023.116013_bib75","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38314","article-title":"T-ALL leukemia stem cell'stemness' is epigenetically controlled by the master regulator SPI1","volume":"7","author":"Zhu","year":"2018","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib76","first-page":"1","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"21","key":"10.1016\/j.biopha.2023.116013_bib77","first-page":"2553","article-title":"Metabolism in stem cell\u2013driven leukemia: parallels between hematopoiesis and immunity. Blood","volume":"141","author":"Rattigan","year":"2023","journal-title":"J. Am. Soc. Hematol."},{"issue":"8","key":"10.1016\/j.biopha.2023.116013_bib78","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1002\/jcp.26265","article-title":"The roles of Wnt\/\u03b2\u2010catenin pathway in tissue development and regenerative medicine","volume":"233","author":"Majidinia","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2023.116013_bib79","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0192623315621192","article-title":"Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index< 1","volume":"44","author":"Zhong","year":"2016","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2023.116013_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221075749","article-title":"Lovastatin inhibits RhoA to suppress canonical Wnt\/\u03b2-catenin signaling and alternative Wnt-YAP\/TAZ signaling in colon cancer","volume":"31","author":"Xiao","year":"2022","journal-title":"Cell Transplant."},{"issue":"7","key":"10.1016\/j.biopha.2023.116013_bib81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.biopha.2023.116013_bib82","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1158\/1078-0432.CCR-14-0877","article-title":"Molecular pathways: aspirin and Wnt signaling\u2014a molecularly targeted approach to cancer prevention and treatment","volume":"21","author":"Gala","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.116013_bib83","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11586540-000000000-00000","article-title":"A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer","volume":"34","author":"Mountzios","year":"2011","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.biopha.2023.116013_bib84","first-page":"2845","article-title":"Impact of small molecules on \u03b2-catenin and E-cadherin expression in HPV16-positive and-negative squamous cell carcinomas","volume":"37","author":"Kramer","year":"2017","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2023.116013_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22905","article-title":"Doxazosin and erlotinib have anticancer effects in the endometrial cancer cell and important roles in ER\u03b1 and Wnt\/\u03b2\u2010catenin signaling pathways","volume":"35","author":"Karaca","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-236","article-title":"Convergence between Wnt-\u03b2-catenin and EGFR signaling in cancer","volume":"9","author":"Hu","year":"2010","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.116013_bib87","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41388-018-0473-z","article-title":"EGF-induced nuclear localization of SHCBP1 activates \u03b2-catenin signaling and promotes cancer progression","volume":"38","author":"Liu","year":"2019","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2023.116013_bib88","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.onc.1208296","article-title":"The AKT\/I\u03baB kinase pathway promotes angiogenic\/metastatic gene expression in colorectal cancer by activating nuclear factor-\u03baB and \u03b2-catenin","volume":"24","author":"Agarwal","year":"2005","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.biopha.2023.116013_bib89","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.biopha.2023.116013_bib90","first-page":"1597","article-title":"Noncanonical \u03b2-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia","volume":"141","author":"Panelli","year":"2023","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2023.116013_bib91","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1541-7786.MCR-17-0362","article-title":"TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting \u03b2-CATENIN and AKT Signaling in Colorectal CancerCross-talk between TNKS, PI3K, and EGFR Inhibitors in CRC","volume":"16","author":"Solberg","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2023.116013_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.217","article-title":"Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer","volume":"6","author":"Sette","year":"2015","journal-title":"Cell death Dis."},{"key":"10.1016\/j.biopha.2023.116013_bib93","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clineuro.2018.02.041","article-title":"Crizotinib and erlotinib inhibits growth of c-Met+\/EGFRvIII+ primary human glioblastoma xenografts","volume":"171","author":"Goodwin","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"17","key":"10.1016\/j.biopha.2023.116013_bib94","doi-asserted-by":"crossref","first-page":"13488","DOI":"10.18632\/oncotarget.24416","article-title":"Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2023.116013_bib95","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.2011.540799","article-title":"Reviewing the safety of erlotinib in non-small cell lung cancer","volume":"10","author":"Reck","year":"2011","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223018115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223018115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:47:07Z","timestamp":1773967627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223018115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":95,"alternative-id":["S0753332223018115"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116013","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.28.555200","asserted-by":"object"}]},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt\/\u03b2-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116013"}}